Valuation: Geron Corporation

Market Cap 911M 797M 735M 677M 1.28B 87.7B 1.31B 8.79B 3.45B 42.94B 3.42B 3.35B 148B P/E 2026 *
-72x
P/E 2027 * 22.7x
Enterprise Value 890M 778M 718M 662M 1.25B 85.68B 1.28B 8.58B 3.37B 41.95B 3.34B 3.27B 144B EV / Sales 2026 *
3.81x
EV / Sales 2027 * 2.23x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 day+1.41%
1 week-7.69%
Current month+12.50%
1 month+22.03%
3 months-14.79%
6 months+9.92%
Current year+9.09%
1 week 1.35
Extreme 1.35
1.51
1 month 1.23
Extreme 1.23
1.62
Current year 1.08
Extreme 1.08
2.01
1 year 1.04
Extreme 1.04
2.01
3 years 1.04
Extreme 1.04
5.34
5 years 0.99
Extreme 0.9899
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 54 07/08/2025
Director of Finance/CFO 59 25/09/2023
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 76 21/05/2010
Director/Board Member 72 28/09/2012
Director/Board Member 55 26/03/2019
Date Insider Type Main position Quantity % Market Cap.
30/6/26 Free

Director

6,103 0.0010%
20/5/26 Free

Director

220,000 0.0343%
20/5/26 Free

Director

220,000 0.0343%
Change 5-day change 1-year change 3-year change Capi.($)
+1.41%-7.69%+13.39%-55.28% 911M
-7.17%-2.63%+49.59%+74.24% 55.98B
+0.24%-5.62%+54.73%+125.15% 53.69B
+0.80%-8.41%+3.57%+425.83% 23.29B
-0.09%-1.61%-18.68%-15.48% 23.15B
-5.95%-0.22%+35.96%-9.58% 20.58B
-1.14%-3.16%+32.88%-28.80% 17.76B
-5.16%-7.00%+177.56%+326.39% 16.09B
-6.91%+2.40%+36.86%+636.97% 15.93B
+0.43%-2.07%+24.79%+188.40% 14B
Average -2.35%-2.03%+41.06%+166.78% 24.14B
Weighted average by Cap. -2.90%-2.22%+43.47%+156.23%

Financials

2026 *2027 *
Net sales 234M 204M 189M 174M 328M 22.51B 335M 2.26B 886M 11.02B 878M 859M 37.96B 333M 291M 269M 248M 467M 32.07B 477M 3.21B 1.26B 15.7B 1.25B 1.22B 54.09B
Net income -13.87M -12.13M -11.19M -10.31M -19.44M -1.34B -19.87M -134M -52.55M -654M -52.09M -50.94M -2.25B 46.53M 40.69M 37.55M 34.59M 65.23M 4.48B 66.67M 449M 176M 2.19B 175M 171M 7.55B
Net Debt -20.97M -18.33M -16.92M -15.59M -29.39M -2.02B -30.04M -202M -79.44M -988M -78.75M -77.01M -3.4B -169M -148M -136M -126M -237M -16.27B -242M -1.63B -640M -7.97B -635M -621M -27.44B
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
17/07/26 US$1.440 +1.41% 4,782,511
16/07/26 US$1.420 0.00% 6,800,693
15/07/26 US$1.420 +2.90% 6,178,427
14/07/26 US$1.380 -2.82% 11,736,079
13/07/26 US$1.420 -5.33% 7,162,331
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
1.440USD
Average target price
3.400USD
Spread / Average Target
+136.11%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GERN Stock